Skip to main content

Adjunctive intra-arterial thrombolysis with endovascular thrombectomy for acute large-vessel occlusion stroke: a network meta-analysis of randomized trials

In brief

Adding artery-delivered alteplase raised excellent stroke outcomes by 40% after thrombectomy

In a network meta-analysis of eight randomized trials involving 2,564 patients, adding intra-arterial alteplase to thrombectomy was associated with a 40% higher likelihood of an excellent 90-day outcome than thrombectomy alone. No strategy significantly improved functional independence, and a clinically important bleeding risk cannot be ruled out; the apparent mortality advantage with tenecteplase over alteplase rests on sparse evidence.

Journal
Frontiers in medicine (Q1)
Published
4 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Junqi Ma, Ruige Li, Chenfei Lu, Jinping Wang, Yankun Chen, Xiaodu Yu
PMID
43054172
DOI
10.3389/fmed.2026.1915195

Why clinicians should know about it

  • Picked for Neurology (clinical) (top studies of the week, 22 November 2026): Randomized-trial synthesis evaluates adjunctive stroke thrombolysis

Abstract

BACKGROUND: While endovascular thrombectomy (EVT) is standard care for acute ischemic stroke due to large vessel occlusion (AIS-LVO), but nearly half of patients with successful reperfusion do not achieve functional independence. Adjunctive intra-arterial thrombolysis (IAT) aims to address residual distal thrombi and microcirculatory impairment; however, the efficacy and safety of IAT in comparison with other thrombolytics remain uncertain. METHODS: We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing EVT alone vs. EVT combined with IAT using alteplase (ALT), tenecteplase (TNK), or urokinase (UK) in AIS-LVO patients. Primary outcomes were excellent clinical outcome (mRS 0-1) and functional independence (mRS 0-2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. RESULTS: Eight RCTs involving 2,564 patients were included. For excellent clinical (mRS 0-1), EVT + IA-ALT ranked highest [surface under the cumulative ranking curve (SUCRA) 96.2%], followed by EVT + IA-TNK (59.8%). Both showed significant benefits over EVT alone [EVT + IA-TNK vs. EVT: RR 1.20, 95% CI 1.05-1.39. EVT + IA-ALT vs. EVT: RR 1.40, 95% CI 1.21-1.63 and EVT + IA-TNK (0.125 mg/kg) vs. EVT: RR 1.54, 95% CI 1.07-2.20. EVT + IA-ALT (0.225 mg/kg) vs. EVT: RR 1.40, 95% CI 1.21-1.63]. For functional independence (mRS 0-2), EVT + IA-ALT also ranked highest, but no combination strategy showed a statistically significant benefit over EVT alone in pairwise comparisons. Regarding safety, point estimates for sICH risk did not differ significantly between combination strategies and EVT alone. However, EVT + IA-TNK demonstrated a statistically significant advantage over EVT + IA-ALT in terms of lower all-cause mortality (RR 1.58, 95% CI 1.01-2.46). CONCLUSIONS: EVT + IA-ALT and EVT + IA-TNK may improve excellent clinical outcome without a statistically significant increase in sICH; however, clinically important bleeding risk cannot be excluded. In exploratory indirect comparisons, EVT + IA-TNK was associated with lower all-cause mortality than EVT + IA-ALT, although this finding is based on sparse evidence and should be interpreted with caution. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420261465567.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.